NY-CONDECO
Condeco , a global leader in workspace scheduling software, is today announcing the launch of its new marketing campaign that is uniquely designed to address the immediate need for businesses to redefine the workplace and respond to the evolving expectations of their employees.
Condeco’s campaign will debut with a new film short that showcases the needs of the modern workplace and contextualizes the new wave of business culture that is turning the traditional office environment on its head. Positioned as a satirical comedy, the film short highlights the growing generational divide that has emerged out of the pandemic, and light-heartedly cements the importance of having an employer that understands and embraces employee needs.
In addition to the launch of this new film, Condeco’s new marketing campaign includes a new consumer report that supports the importance of fostering a workplace that respects the desires of its employees, with hybrid work opportunities at its core. As full-time remote work becomes a pandemic pastime, this report’s findings underscore the need for business leaders to prioritize employee happiness, mental health, and digital technology as they adopt hybrid work models.
“It’s no secret that there has been a seismic shift in how we work” said Lynda Lowe, CMO at Condeco. “Work is now an outcome that is no longer defined by a single physical location and there is a growing tension point between business leaders who are trying to force a return to the office and their employees who want to be able to work flexibly. But this does not mean that leaders should discount the value of the office altogether. Instead, leaders must understand the value of the office has shifted to providing a safe space for employee collaboration. The past two years have taught us that empowering employees with time and space to do this at their choosing is key to supporting their mental health and well-being, as well as driving enhanced business culture and social interaction.”
Condeco’s new marketing campaign follows the brand’s repositioning in 2021 , which recognized the immediate need for employers to provide their employees with the flexibility to work from anywhere. Delivering on its mission to help businesses redefine their workplace, Condeco acquired ProxyClick in January 2022 to expand Condeco’s workspace solutions for the enterprise, enabling the company to drive an end-to-end employee and guest experience with the connected office – and ultimately, help businesses prepare for the future at work.
Condeco’s new film will air across connected TV and social channels starting on Tuesday, April 12, 2022. Media planned and bought by Hubble , part of What’s Possible Group. The film was produced by Arts & Sciences and directed by Casey Storm, who is known for his work with brands including Paypal, Apple, Hulu, Expedia, and more.
To view the full broadcast, please see here: https://youtu.be/HunkSOvLJ4M . To learn more about Condeco’s new report on hybrid work, please see here .
About Condeco
Condeco is the global leader in enterprise level workspace solutions. Our software is designed to equip everyone with the tools they need for a seamless end to end experience in today’s office. By giving people control over flexible work, we deliver the certainty people need, enable the collaboration teams crave, and facilitate the insights on capacity that employers demand. From visitor management to workspace booking to office optimization, we are trusted by over 2000 of the world’s largest companies to realize their future at work.
About Arts & Sciences
Arts & Sciences was started over a decade ago as a boutique production company that specializes in producing award-winning advertising content, music videos, fine art projects, original documentaries, and feature films. Located in Los Angeles, NYC, and London, Arts & Sciences represents a diverse group of top directors and creators and has been named a Creativity A-List Production Company five times. Every major advertising award show has recognized its work, including Cannes Lions, Clio, AICP, D&AD, The One Show, and the Andys. Their original content work has been featured in the New Frontiers showcase at the Sundance Film Festival, The New Yorker, Nowness, and Purple Magazine. Arts & Sciences has produced work for every major global brand, such as Google, Apple, Facebook, Nike, AT&T, Samsung, Volkswagen, Ford, Toyota, American Express, MLB, the NFL, and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005251/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
